Richard Bourgon

Freenome (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

39h-index24.3kcitations166works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(39), Cancer Immunotherapy and Biomarkers(27), Ferroptosis and cancer prognosis(23), Epigenetics and DNA Methylation(20), RNA modifications and cancer(20)

Publications166 total

Clinical performance of an improved colorectal cancer (CRC) screening blood test.
Journal of Clinical Oncology·2026
Abstract A045: Unlocking deep learning for cell-free DNA-based early colorectal cancer detection
Clinical Cancer Research·2025
Towards designing improved cancer immunotherapy targets with a peptide-MHC-I presentation model, HLApollo
Nature Communications·2024· 7 citedOpen Access
Automated Clinical Data Extraction with Knowledge Conditioned LLMs
arXiv (Cornell University)·2024· 3 citedOpen Access
HLApollo: Towards designing improved cancer immunotherapy targets with a superior peptide-MHC-I presentation model
Zenodo (CERN European Organization for Nuclear Research)·2024Open Access
Multi-Cancer Early Detection
Advances in Molecular Pathology·2023
HLApollo: Towards designing improved cancer immunotherapy targets with a superior peptide-MHC-I presentation model
Zenodo (CERN European Organization for Nuclear Research)·2023Open Access
Figures S1,2,4-8 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Supplemental Methods from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Figures S1,2,4-8 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Figure S3 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Supplementary Data from Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15<sup>+</sup> Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
2023Open Access
Table S1 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Supplementary Data from Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15<sup>+</sup> Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
2023Open Access
Figure S3 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Supplementary Data from Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15<sup>+</sup> Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
2023Open Access
Data from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Table S2 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
Supplementary Data from Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15<sup>+</sup> Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
2023Open Access
Table S1 from Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Zora Modrušan(14), Peter M. Haverty(10), Frédéric J. de Sauvage(9), Yinghui Guan(7), Robert L. Yauch(7), Somasekar Seshagiri(7), Lukas C. Amler(7), Sanjeev Mariathasan(6), Shannon J. Turley(6), Yulei Wang(6), Hartmut Koeppen(6), Suchit Jhunjhunwala(6), Ira Mellman(6), Priti S. Hegde(6), Howard M. Stern(6), Richard M. Neve(6), Mark R. Lackner(6), David S. Shames(5), Robert Gentleman(5), Zemin Zhang(5)